| 2026-08-25today | Dose Escalation Study of CLR 131 in Pediatric Relapsed/Refractory Malignant Tumors Including Neuroblastoma and Sarcomas | CLRBCellectar Biosciences, Inc. | Phase 1 | Solid Tumors | Active, not recruiting |
| 2026-08-25today | A Study to Investigate the Efficacy and Safety of Rilzabrutinib in Adult Participants With Graves' Disease | SNYSanofi | Phase 2 | Graves' Disease | Recruiting |
| 2026-08-26in 1 d | Effect of Maridebart Cafraglutide on the Heart's Electrical Activity | AMGNAmgen | Phase 1 | Overweight | Active, not recruiting |
| 2026-08-27in 2 d | Teplizumab in Pediatric Stage 2 Type 1 Diabetes | SNYSanofi | Phase 4 | Type 1 Diabetes | Active, not recruiting |
| 2026-08-28in 3 d | A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC | AZNAstraZeneca | Phase 1/2 | Lung Cancer | Active, not recruiting |
| 2026-08-28in 3 d | A Study to Investigate the Effect of Elecoglipron on Rosuvastatin and Atorvastatin in Healthy Participants | AZNAstraZeneca | Phase 1 | Healthy Participants | Active, not recruiting |
| 2026-08-30in 5 d | SpaceIT Hydrogel System for Perirectal Spacing | BSXBoston Scientific Corporation | Not applicable | Prostate Cancer | Active, not recruiting |
| 2026-08-30in 5 d | Study to Investigate the Safety, Tolerability, and Pharmacokinetics of GB-7624 in Healthy Adult Participants | GENBGenerate Biomedicines | Phase 1 | Atopic Dermatitis | Active, not recruiting |
| 2026-08-30in 5 d | An Open-label Long-term Follow-up Study of SAT-3247 for Participants With Duchenne Muscular Dystrophy Including Those Who Participated in SAT-3247-CL-101 | MSLESatellos Bioscience, Inc. | Phase 2 | Duchenne Muscular Dystrophy | Enrolling by invitation |
| 2026-08-30in 5 d | MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide) | PFEPfizer | Phase 3 | Multiple Myeloma | Recruiting |
| 2026-08-30in 5 d | A Study to Learn About Study Medicine Lorlatinib, as a First-line Treatment in Chinese Adults With ALK-positive a/mNSCLC | PFEPfizer | — | Lung Cancer | Active, not recruiting |
| 2026-08-30in 5 d | A Retrospective Assessment of OviTex PRS (OviTex) | TELATela Bio Inc | — | Reconstructive Surgical Procedures | Active, not recruiting |
| 2026-08-31in 6 d | Study to Assess the Efficacy & Safety of KHK4951 in Patients With Neovascular Age-Related Macular Degeneration | 4151.TKyowa Kirin Co., Ltd. | Phase 2 | Age-Related Macular Degeneration | Active, not recruiting |
| 2026-08-31in 6 d | Study to Assess the Efficacy & Safety of KHK4951 in Patients With Diabetic Macular Edema | 4151.TKyowa Kirin Co., Ltd. | Phase 2 | Diabetic Macular Edema (DME) | Active, not recruiting |
| 2026-08-31in 6 d | Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04) | 4568.TDaiichi Sankyo | Phase 3 | Gastroesophageal Cancer | Active, not recruiting |
| Aug 2026≤ 6 d | A Study Evaluating the Safety, Pharmacokinetics (PK), and Preliminary Efficacy of ABBV-399 in Participants With Advanced Solid Tumors | ABBVAbbVie | Phase 1 | Solid Tumors | Active, not recruiting |
| Aug 2026≤ 6 d | A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma. | ABBVAbbVie | Phase 3 | Multiple Myeloma | Active, not recruiting |
| Aug 2026≤ 6 d | RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD) | ABBVAbbVie | Phase 2 | Age-Related Macular Degeneration | Active, not recruiting |
| Aug 2026≤ 6 d | A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab | ABBVAbbVie | Phase 3 | Atopic Dermatitis | Recruiting |
| Aug 2026≤ 6 d | A Study to Assess Safety and Effectiveness of HArmonyCa Lidocaine Injectable Gel for Restoration and/or Creation of Mid-Face Volume in Adult Participants | ABBVAbbVie | Phase 3 | Mid Face Volume Deficit | Active, not recruiting |
| Aug 2026≤ 6 d | A Clinical Study to Evaluate the Effect and Side Effect of a New Artificial Tear Formulation (ABBV-444) Compared to Refresh Optive Unit Dose in Adult Participants With Dry Eye Disease | ABBVAbbVie | Phase 3 | Dry Eye Disease | Active, not recruiting |
| Aug 2026≤ 6 d | ATI-045 Versus Placebo in Patients With Moderate-to-Severe Atopic Dermatitis | ACRSAclaris Therapeutics, Inc. | Phase 2 | Atopic Dermatitis | Active, not recruiting |
| Aug 2026≤ 6 d | To Evaluate the Efficacy of Three Times Weekly (TIW) Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis | AKBAAkebia Therapeutics | Phase 3 | Chronic Kidney Disease | Active, not recruiting |
| Aug 2026≤ 6 d | ALTO-100 in Bipolar Disorder With Depression (BD-D) | ANROAlto Neuroscience | Phase 2 | Bipolar Disorder I or II With a Major Depressive Episode | Recruiting |
| Aug 2026≤ 6 d | Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Buprenorphine/Naloxone or Methadone | AVIRAtea Pharmaceuticals, Inc. | Phase 1 | Healthy Volunteer Study | Recruiting |
| 2026-08-31in 6 d | A Real-World Assessment of the Demographic, Clinical Characteristics and Outcomes of a Brazilian Cohort of Previously Untreated Extensive Stage-Small Cell Lung Cancer Receiving Durvalumab Combined With Platinum-Etoposide in (ES-SCLC) in Brazil | AZNAstraZeneca | — | Lung Cancer | Active, not recruiting |
| 2026-08-31in 6 d | Boosting Regional Integration for COP D Care Through Guided Implementation and Audit of Post Exacerbation Transition Bundle | AZNAstraZeneca | — | COPD | Active, not recruiting |
| Aug 2026≤ 6 d | NE3107 in Adults With Neurological Symptoms of Long COVID | BIVIBioVie Inc. | Phase 2 | Long COVID | Active, not recruiting |
| Aug 2026≤ 6 d | A Study of BL1332 on Capsaicin-Induced Ocular Pain in Healthy Trial Participants | BLCOBausch & Lomb Incorporated | Phase 1 | Healthy | Recruiting |
| Aug 2026≤ 6 d | Rapid Drug Desensitization Study in Adults Experiencing Hypersensitivity Reactions to Palynziq | BMRNBioMarin Pharmaceutical | Phase 4 | Phenylketonuria, PKU | Active, not recruiting |
| 2026-08-31in 6 d | A Phase 1 Study of Navlimetostat Tablet Formulations | BMYBristol-Myers Squibb | Phase 1 | Healthy Participants | Recruiting |
| Aug 2026≤ 6 d | Respiration Measured Via End-tidal CO2 and Spirometry Study (RESPI) | BSXBoston Scientific Corporation | — | Respiration Rate Detection | Recruiting |
| Aug 2026≤ 6 d | A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec | CADLCandel Therapeutics, Inc. | Phase 2 | Prostate Cancer | Recruiting |
| Aug 2026≤ 6 d | A Study Comparing the Effect and Safety of Linaprazan Glurate to Lansoprazole in Participants With Erosive Esophagitis (EE) Due to Gastroesophageal Reflux Disease (GERD) | CINPHA.STCinclus Pharma Holding AB | Phase 3 | GERD (Gastroesophageal Reflux Disease) | Active, not recruiting |
| Aug 2026≤ 6 d | Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers | CORTCorcept Therapeutics | Phase 2 | Ovarian Cancer | Recruiting |
| Aug 2026≤ 6 d | Evaluation of Miricorilant on Liver Fat in Patients With MASLD | CORTCorcept Therapeutics | Phase 1 | MASH / Nonalcoholic Steatohepatitis | Active, not recruiting |
| Aug 2026≤ 6 d | CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL) | CRISCuris, Inc. | Phase 1/2 | Relapsed Hematologic Malignancy, Refractory Hematologic Malignancy, Relapsed Primary Central Nervous System Lymphoma, Refractory Primary Central Nervous System Lymphoma | Recruiting |
| Aug 2026≤ 6 d | A Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM) | CYTKCytokinetics | Phase 3 | Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy | Active, not recruiting |
| Aug 2026≤ 6 d | PF614 Analgesic Activity in Acute Postoperative Pain (PF614-301) | ENSCEnsysce Biosciences | Phase 3 | Postoperative Pain, Acute | Recruiting |
| 2026-08-31in 6 d | A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors | EXELExelixis | Phase 1 | Renal Cell Carcinoma | Active, not recruiting |
| Aug 2026≤ 6 d | Data Collection of New Spectral CT Imaging Method | GEHCGE Healthcare | — | Computed Tomography | Recruiting |
| Aug 2026≤ 6 d | Study of Novel Treatment Combination Therapies in Participants With Head and Neck Squamous Cell Carcinoma Regardless of PD-L1 Expression Status; Substudy-01 | GILDGilead Sciences | Phase 2 | Head and Neck Cancer | Active, not recruiting |
| Aug 2026≤ 6 d | Safety and Efficacy of iDose® TR With Cataract Surgery vs. Cataract Surgery Alone | GKOSGlaukos Corporation | Phase 4 | Glaucoma | Recruiting |
| Aug 2026≤ 6 d | Aleniglipron Phase 2 Body Composition Study | GPCRGasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics | Phase 2 | Overweight | Active, not recruiting |
| Aug 2026≤ 6 d | Clinical Study to Investigate the Antihypersensitivity Efficacy of a Novel Dentifrice | HLNHALEON | Phase 3 | Dentin Hypersensitivity | Active, not recruiting |
| Aug 2026≤ 6 d | Study Evaluating the Efficacy and Safety of Chloroprocaine HCl Ophthalmic Gel 3% vs Proparacaine Ophthalmic Solution 0.5% Plus Subconjunctival Lidocaine in Patients Undergoing Intravitreal Injections | HROWHarrow Inc | Phase 4 | Age-Related Macular Degeneration | Enrolling by invitation |
| Aug 2026≤ 6 d | Clinical Trial on Agitation in Alzheimer's Dementia | IGCIGC Pharma, LLC | Phase 2 | Alzheimer's Disease | Recruiting |
| Aug 2026≤ 6 d | Interference and Stability Evaluation of the Intelligent Fingerprinting Drug Screening System | INBSIntelligent Bio Solutions Inc. | Not applicable | Interference With Routine Analytical Tests, Stability of in Vitro Diagnostic Reagents, Illicit Drug Use | Enrolling by invitation |
| 2026-08-31in 6 d | A Study to Assess the Safety and Efficacy of IPN10200 in Adult Participants With Moderate to Severe Upper Facial Lines | IPN.PAIpsen | Phase 1/2 | Moderate to Severe Upper Facial Lines | Active, not recruiting |
| Aug 2026≤ 6 d | A Study to Understand the Utility of the Force Feedback Instruments in Robotic Procedures Using da Vinci 5 Robot | ISRGIntuitive Surgical | — | Hernia, Inguinal, Hernia, Ventral, Colorectal, Thoracic, Gynecologic, Partial Nephrectomy | Recruiting |
| Aug 2026≤ 6 d | Study of VYD2311 for the Prevention of COVID-19 | IVVDInvivyd, Inc. | Phase 3 | COVID-19 | Active, not recruiting |
| Aug 2026≤ 6 d | Safety and Serum Virus Neutralizing Antibody Responses of VYD2311, a COVID-19 Vaccine, and Coadministered VYD2311 With a COVID-19 Vaccine | IVVDInvivyd, Inc. | Phase 3 | COVID-19 | Recruiting |
| 2026-08-31in 6 d | Tampon Safety-in-Use Study | KMBKimberly-Clark Corporation | Not applicable | Menstruation | Recruiting |
| Aug 2026≤ 6 d | A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) - DAYBREAK | KODKodiak Sciences Inc | Phase 3 | Age-Related Macular Degeneration | Active, not recruiting |
| Aug 2026≤ 6 d | Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma | KPTIKaryopharm Therapeutics Inc | Phase 3 | Endometrial Cancer | Active, not recruiting |
| Aug 2026≤ 6 d | KYSA-1: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis | KYTXKyverna Therapeutics | Phase 1/2 | Lupus Nephritis | Active, not recruiting |
| Aug 2026≤ 6 d | A Study of LY3971297 in Healthy Participants | LLYEli Lilly and Company | Phase 1 | Obesity | Active, not recruiting |
| Aug 2026≤ 6 d | Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2) | LLYEli Lilly and Company | Phase 3 | Type 2 Diabetes | Active, not recruiting |
| Aug 2026≤ 6 d | Comparing the Extent to Which Three Different Formulations of LY4100511 (DC-853) Are Made Available in the Body, Alone and in the Presence of a Drug That Reduces Stomach Acid | LLYEli Lilly and Company | Phase 1 | Healthy Participants | Active, not recruiting |
| Aug 2026≤ 6 d | A Study of LY3867070 in Healthy Participants | LLYEli Lilly and Company | Phase 1 | Healthy | Recruiting |
| Aug 2026≤ 6 d | A Study of the Pharmacokinetics and Safety of LY3537031 in Participants With Normal Liver Function and With Mild, Moderate, or Severe Liver Impairment | LLYEli Lilly and Company | Phase 1 | Healthy, Hepatic Insufficiency | Recruiting |
| Aug 2026≤ 6 d | A Study of Retinal Imaging to Detect Abnormal Protein Deposits Associated With Alzheimer's Disease | LLYEli Lilly and Company | — | Cognitive Dysfunction, Memory Disorders | Not yet recruiting |
| Aug 2026≤ 6 d | A Study of Remternetug (LY3372993) in Healthy Chinese Participants | LLYEli Lilly and Company | Phase 1 | Healthy | Active, not recruiting |
| Aug 2026≤ 6 d | A Study of Eltrekibart (LY3041658) in Healthy Participants | LLYEli Lilly and Company | Phase 1 | Healthy | Active, not recruiting |
| Aug 2026≤ 6 d | Safety and Efficacy of VDPHL01 in Males and Females With AGA | MANEVeradermics, Inc. | Phase 2 | Androgenetic Alopecia, AGA, Male Pattern Baldness | Active, not recruiting |
| Aug 2026≤ 6 d | Modified Platform Trial Evaluating PpLHACM and SOC Versus SOC Alone in the Treatment of Nonhealing DFUs | MDXGMiMedx Group, Inc. | Not applicable | Diabetic Foot Ulcer, Diabetic Foot, Foot Ulcer Due to Type 2 Diabetes Mellitus, Foot Ulcer, Diabetic, Foot Ulcer | Recruiting |
| Aug 2026≤ 6 d | A Trial Evaluating Brelovitug vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection (AZURE-4) | MIRMMirum Pharmaceuticals, Inc. | Phase 3 | Chronic Hepatitis D Infection | Active, not recruiting |
| Aug 2026≤ 6 d | PREEMIE: Study for Treatment of PDA in Premature Infants | MMSIMerit Medical Systems, Inc. | Not applicable | Patent Ductus Arteriosus (PDA) | Active, not recruiting |
| 2026-08-31in 6 d | A Study of NX-1607 in Adults With Advanced Malignancies | NRIXNurix Therapeutics, Inc. | Phase 1 | Ovarian Cancer | Recruiting |
| Aug 2026≤ 6 d | LAMBDA 002 (Lung Registry) Study | NTRANatera, Inc. | — | Lung Transplant Rejection | Active, not recruiting |
| 2026-08-31in 6 d | A Two-armed Real-world Study of Ozempic (OW Semaglutide) to Evaluate Its Adherence and Persistence Compared With Other Anti-diabetic Drugs Among Adult T2DM Patients in China | NVONovo Nordisk A/S | — | Type 2 Diabetes | Enrolling by invitation |
| 2026-08-31in 6 d | A Study to Learn Safety and Immune Response to Study Vaccine -RSVpreF in Adults at High Risk of Severe RSV Disease. | PFEPfizer | Phase 3 | Respiratory Syncytial Virus | Recruiting |
| 2026-08-31in 6 d | A Study to Compare the Blood Levels of Two Dosage Formulations of the Study Medicine in Healthy Adults | PFEPfizer | Phase 1 | Migraine | Recruiting |
| Aug 2026≤ 6 d | Safety of RAD301 in Healthy Human Volunteers and Patients With Pancreatic Cancer or Other Solid Tumors | RADXRadiopharm Theranostics, Ltd | Phase 1 | Pancreatic Cancer | Recruiting |
| Aug 2026≤ 6 d | A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body | RCUSArcus Biosciences, Inc. | Phase 3 | Advanced Upper Gastrointestinal Tract Adenocarcinoma | Active, not recruiting |
| Aug 2026≤ 6 d | Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS) | RIGLRigel Pharmaceuticals | Phase 1/2 | Low Risk Myelodysplastic Syndromes | Recruiting |
| 2026-08-31in 6 d | OMNI 3.1 Surgical System in Subjects With Primary Open-Angle Glaucoma | SGHTSight Sciences, Inc. | Not applicable | Glaucoma | Recruiting |
| 2026-08-31in 6 d | Validation of Chlamydia Diagnostic Codes in TriNetX US EHR Data | SNYSanofi | — | Chlamydial Infections | Recruiting |
| Aug 2026≤ 6 d | OCS Heart EXPAND + CAP Continued Follow-Up | TMDXTransMedics | — | Heart Transplant | Active, not recruiting |
| 2026-08-31in 6 d | Study of Avutometinib (VS-6766) +Defactinib With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer | VSTMVerastem, Inc. | Phase 1/2 | Pancreatic Cancer | Active, not recruiting |
| Aug 2026≤ 6 d | A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder | XENEXenon Pharmaceuticals Inc. | Phase 3 | Major Depressive Disorder | Recruiting |
| Aug 2026≤ 6 d | PMCF Study on the Safety, Performance and Clinical Benefits Data of the ComposiTCP | ZBHZimmer Biomet | — | Rotator Cuff Repairs | Recruiting |
